Microarrays

The PEPperCHIP® Transglutaminase Microarray is based on 6 transglutaminase variants (hFXIII, hTG1, hTG2, hTG3, hTG4 and hTG6) and can be used for

  • high resolution epitope mapping of anti-transglutaminase antibodies
  • antibody specificity analysis with 6 different transglutaminase antigens
  • serum antibody screening for anti-transglutaminase antibodies
  • isotype-specific IgG and IgA profiling from serum and plasma
  • correlation of anti-transglutaminase antibody responses with pathogenesis

The standard slide format of PEPperCHIP® Transglutaminase Microarrays facilitates application with standard lab infrastructures and most microarray scanners. Additional PEPperCHIP® Accessories support the straightforward use of the state-of-the-art peptide microarray solutions to ensure optimized assay conditions and best data quality.

Read more about PEPperCHIP Epitope Mapping
Poster presentation at GRC, 2016 (Girona, Spain)

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • MEDICA

    13.11.2017 - 16.11.2017
    Düsseldorf, Germany

  • Gordon Research Conference on: Transglutaminases in Human Disease Processes

    16.06.2018 - 17.06.2018
    Les Diablerets, Switzerland